Platelets and phospholipids in tissue factor-initiated thrombin generation.
The influence of platelets on tissue factor (TF)-initiated thrombin generation in a reconstituted model of blood coagulation and in whole blood was evaluated. No thrombin generation was observed over 15 min in the reconstituted model when either TF or platelets and phospholipids were omitted. At 25 pM TF, the rates of thrombin generation were platelet and PCPS concentration-dependent and achieved maximum (1.0 nM/s) in the physiological range of platelet concentration. Similar rates were achieved in the absence of platelets when 1-2 microM phospholipid was used. However, the maximum rates of thrombin generation (5.2-6.0 nM/s) and the shortest initiation phase (1 min) were attained between 25 and 100 microM phospholipid. In the reconstituted model, an increase in platelet concentration from 0.125 x 10(8)/ml to 0.5 x 10(8)/ml decreased the duration of the initiation phase (in the absence of phospholipids) from 4.3 min to 2 min. Further increases in platelet concentration did not affect this phase. Sequential whole blood studies were conducted in blood of a chemotherapy patient who developed reduced platelet counts. The TF (12.5 pM) initiated clotting of patient's blood was accelerated from approximately 10 min to 5 min when the platelet concentration increased from 0.05 x 10(8)/ml to 0.11 x 10(8)/ml. Clotting times were essentially unchanged for platelet concentrations exceeding 0.5 x 10(8)/ml (range 0.5-3.1 x 10(8)/ml). Similarly, clotting of whole blood obtained from healthy volunteers was not affected by the platelet count, which varied from 1.5 x 10(8)/ml to 3.1 x 10(8)/ml (4.0+/-0.5 min). The data obtained in both models are consistent with in vivo observations that clinical bleeding is most likely to occur at platelet counts <0.1 x 10(8)/ml.
Butenas
S
S
University of Vermont, Department of Biochemistry, Burlington 05405-0068, USA.
Branda
R F
RF
van't Veer
C
C
Cawthern
K M
KM
Mann
K G
KG
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001685:Biological Factors / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006490:Hemostatics / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D010198:Pancytopenia / Q000097:blood / Q000139:chemically induced; D010743:Phospholipids / Q000502:physiology*; D010976:Platelet Count; D013917:Thrombin / Q000096:biosynthesis* / Q000187:drug effects; D013925:Thromboplastin / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001685:Biological Factors; D006490:Hemostatics; D010743:Phospholipids; D013925:Thromboplastin; D013917:Thrombin